|
|
|
|
11th European AIDS Conference
Madrid
October 24-27, 2007 |
|
|
- An Open, Randomized, Two-Period, Crossover Study in Two Cohorts to Investigate the Effect of Steady-State TMC125 (etravirine) and the Combination of TMC125/Darunavir/Ritonavir on the Steady-State Pharmacokinetics of Oral Maraviroc in Healthy Subjects - (11/29/06)
 
- Low-Level HIV-1 Viral Load Monitoring in Cerebrospinal Fluid: Possible Correlation to Antiretroviral Drug Penetration - (11/27/06)
 
- TMC278, a next-generation NNRTI, demonstrates potent and sustained efficacy in antiretroviral (ARV)-naive patients: Week 48 primary analysis of study TMC278-C204 - (11/27/06)
 
- Lower lipid levels in antiretroviral (ARV)-naive patients receiving the investigational NNRTI TMC278 versus efavirenz (EFV) - (11/27/06)
 
- Tipranavir/r (TPV/r) maintains long term virological suppression
- Three year follow-up of RESIST - (11/26/06)
 
- Improving the prediction of virologic response to tipranavir: the development of a tipranavir weighted score - (11/26/06)
 
- Genotypic tipranavir scores as predictors of response - (11/26/06)
 
- Risk Factors for Kidney Complications - Written by Mark Mascolini - (11/20/06)
 
- Hepatic profile of tipranavir in treatment experienced HIV-1 infected individuals - (11/19/06)
 
-
Linear modeling to estimate the contribution of each drug component of the regimens of highly treatment-experienced patients in RESIST - (11/19/06)
 
-
Patients who responded to tipranavir/r (500/200 mg BID) plus new enfuvirtide (ENF) at Week 16 of RESIST studies maintain superior virologic and immunologic outcomes through Week 96; effects of adding 1 new class to potent protease inhibitor in highly treatment-experienced patients - (11/19/06)
 
- Predictors of New Darunavir Resistance Mutations Upon Darunavir Failure - (11/08/06)
 
- Long-Term, Low-Dose Treatment With Pegylated Interferon alfa-2b Leads to a Significant Reduction in Fibrosis and Inflammatory Scores in Chronic Hepatitis C Nonresponder Patients With Fibrosis or Cirrhosis - (11/08/06)
 
- Co-Receptor Tropism Predictions Based on V3 Loop Sequence in Antiretroviral-Experienced Patients are Specific but Insensitive for the Detection of CXCR4-using Variants - (11/05/06)
 
- Insulin Resistance Imperils Response to Interferon in People With HCV/HIV - (11/04/06)
 
- Spontaneous HCV Clearance With HIV Lower Than Previously Thought? - Written by Mark Mascolini - (11/1/06)
 
- Body Composition Changes in ARV-Naive Subjects Treated with Atazanavir or Atazanavir/Ritonavir-Based Once-Daily HAART: 96-Week CT and DEXA Data - (10/31/06)
 
- Once-Daily Fosamprenavir (FPV) Boosted with Either 100mg or 200mg of Ritonavir (r) Along with Abacavir (ABC)/Lamivudine (3TC): 48 Week Safety and Efficacy Results from COL100758 - (10/30/06)
 
-
Single agent lopinavir/ritonavir (LPV/r) is as effective at maintaining viral suppression as continuation of standard ART at 24 weeks in patients who already have HIV RNA <50 copies/mL - (10/30/06)
 
- Single Agent Therapy (SAT) with Lopinavir/ritonavir (LPV/r) Controls HIV-1 Viral Replication in the Female Genital Tract - (10/30/06)
 
- Switching from Combivir (CBV, AZT/3TC) to Truvada (TVD, TDF/FTC) Maintains Viral Suppression, Prevents and Reverses Limb Fat Loss, and Improves Biochemical Parameters: Results of a 48 Week Randomised Study - (10/30/06)
 
- High Death Risk With HIV, HCV, and Decompensated Cirrhosis - Written by Mark Mascolini - (10/29/06)
 
-
Do HCV Genotype and Load Affect Mortality With HIV? - Written by Mark Mascolini - (10/29/06)
 
- Switch to Atripla from Undetectable HAART - (10/29/06)
 
- Continuation of BID Boosted PI vs Switch to Once-daily Boosted Atazanavir in Subjects with Truncal Adiposity - (10/29/06)
 
- Good News and Bad News on Survival With Neurologic AIDS - Written by Mark Mascolini - (10/29/06)
 
- After First Year of HAART in 1996, Mortality Stable With Advanced Disease - Written by Mark Mascolini - (10/29/06)
 
- An assessment of HIV-HCV co-infection management in Spain: The ABHACO survey; 61-69% OF HIV infected patients are co-infected with the HCV too - (10/29/06)
 
- Long-term (4 years) efficacy of Lopinavir/ritonavir monotherapy for maintenance of HIV suppression - (10/29/06)
 
- Boosted Versus Unboosted Atazanavir After Long-Term Lopinavir - Written by Mark Mascolini - (10/26/06)
 
-
ARTEMIS: Efficacy and safety of lopinavir (BID vs QD) and darunavir (QD) in antiretroviral-naive patients
- (10/29/06)
 
-
ARTEMIS Study: Once-Daily Darunavir, Once-Daily Lopinavir, and Twice-Daily Lopinavir Compared - Written by Mark Mascolini - (10/26/06)
 
- Prognostic Factors of Virological Success in Antiretroviral-naive Patients Receiving LPV Monotherapy in the MONARK trial - (10/29/06)
 
- Lopinavir/ritonavir monotherapy versus lopinavir/ritonavir and two nucleosides for maintenance therapy of HIV. Ninety-six week results of a randomized, controlled, open-label clinical trial (OK04 Study) (10/26/06)
 
- Pooled 24-week results of DUET-1 and DUET-2: efficacy of TMC125 (etravirine; ETR) in treatment-experienced HIV-1-infected patients (10/26/06)
 
- The Incidence of Severe Liver Enzyme Abnormalities and Hepatic Adverse Events in the Maraviroc Clinical Development Programme (10/26/06)
 
- Impact of baseline NNRTI mutations on the virological response to TMC125 (etravirine; ETR) in the DUET-1 and DUET-2 Phase III clinical trials (10/26/06)
 
- Efficacy of Raltegravir, an HIV Integrase Inhibitor, in Combination with Regimens Containing Enfuvirtide, Darunavir, or Tipranavir in Patients with Triple-class Resistant Virus: Combined Results from BENCHMRK-1 and BENCHMRK-2 (10/26/06)
 
- Pooled 24-week results of DUET-1 and DUET-2: TMC125 (etravirine; ETR) safety and tolerability in treatment-experienced, HIV-1-infected patients (10/26/06)
 
- Why Do British Docs Follow Antiretroviral Rules Less and Less? - Written by Mark Mascolini - (10/25/06)
 
- Saquinavir/r (SQV/r) vs lopinavir/r (LPV/r) plus emtricitabine/tenofovir (FTC/TDF) as initial therapy in HIV-1 infected patients The Gemini Study (10/25/06)
 
-
Long-Term Kidney Damage From Indinavir But Not Tenofovir - Written by Mark Mascolini - (10/25/06)
 
- Cocaine Boosts Cardiovascular Risk in Spanish Patients With HIV - Written by Mark Mascolini - (10/25/06)
 
- Lopinavir Monotherapy Fails More in People With Non-B Subtypes - Written by Mark Mascolini - (10/25/06)
 
- Final Gemini Study Results Confirm Boosted Invirase Was as Effective as Kaletra While Providing an Improved Triglyceride Profile for HIV Patients (press release from Roche) - Written by Mark Mascolini - (10/25/06)
 
- Combined 24-Week Efficacy Data on the Integrase Inhibitor Raltegravir - Written by Mark Mascolini - (10/25/06)
 
- Efficacy and Safety of Maraviroc (MVC) Plus Optimized Background Therapy (OBT) In Viraemic, Antiretroviral Treatment-Experienced Patients Infected with CCR5-Tropic (R5) HIV-1 in Europe, Australia and North America (MOTIVATE 2): 48-Week Results
(10/25/06)
 
- Two Tools for Sharpening Darunavir Response Predictions - Written by Mark Mascolini - (10/24/06)
 
- Response to Nonnucleoside TMC278 Sustained Through 48 Weeks - Written by Mark Mascolini - (10/24/06)
 
- Four Double-DUET Analyses Give Closer Look at New NNRTI - Written by Mark Mascolini - (10/24/06)
 
|
|
|
|
|
|
|
|
|